Stockreport

BioCryst: The $700 Million Pivot From Oral Convenience To Injectable [Seeking Alpha]

BioCryst Pharmaceuticals, Inc.  (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations
PDF BCRX's acquisition of Astria and STAR-0215 offers potential upside if Phase 3 data deliver, but execution risk remains high. ORLADEYO delivered $601 million in 2025 r [Read more]